Schrodinger, Inc. Stock Price, News & Analysis

Schrödinger (Nasdaq: SDGR) announced significant developments, including an expanded collaboration with Bristol Myers Squibb to target neurology and a new partnership with Otsuka Pharmaceutical for CNS diseases. The company reported progress on its LRRK2 inhibitor program aimed at Parkinson's disease and emphasized its 2022 achievements, such as FDA clearance for SGR-1505 and multiple new drug discovery collaborations. For 2023, Schrödinger aims to advance its clinical trials and expand its collaborative drug discovery efforts, with financial results scheduled for February 28, 2023.

Schrödinger, Inc. (Nasdaq: SDGR) announced the grant of non-statutory stock options for 26,350 shares to seven newly hired employees on December 15, 2022. This initiative, part of the 2021 Inducement Equity Incentive Plan approved by the compensation committee, serves as an employment inducement. The options have an exercise price of $19.89 and a ten-year term, vesting over four years. Schrödinger leverages its advanced computational platform for discovering therapeutics and materials, aiming to improve the drug development process efficiently.

Schrödinger, Inc. (Nasdaq: SDGR) presented promising preclinical data on its CDC7 inhibitor, SGR-2921, at the American Society of Hematology meeting. The data demonstrate strong anti-tumor activity in multiple acute myeloid leukemia (AML) models, both as a monotherapy and in combination with standard care agents. Plans are in place to submit an Investigational New Drug (IND) application to the FDA in the first half of 2023, followed by a Phase 1 clinical trial for patients with relapsed/refractory AML.

On November 15, 2022, Schrödinger granted 32,165 non-statutory stock options to eight newly hired employees as part of its 2021 Inducement Equity Incentive Plan. The options have an exercise price of $22.27 per share, matching the stock's closing price on the grant date. Vesting for U.S. employees occurs in monthly installments over four years, while international employees will vest annually over three years. Schrödinger utilizes a physics-based computational platform to enhance drug discovery and materials development, with a workforce of around 800 across 70 countries.

Schrödinger (Nasdaq: SDGR) announced participation in a fireside chat at the Jefferies 13th Annual London Healthcare Conference on November 16, 2022, at 3:50 p.m. GMT (10:50 a.m. ET). The event aims to showcase Schrödinger's innovative physics-based computational platform that significantly enhances drug and material discovery. Interested parties can access the live discussion on the company's website, where it will also be archived for about seven days. Schrödinger operates globally with around 800 employees, focusing on unmet medical needs through its collaborative and proprietary programs.

Schrödinger, Inc. (SDGR) reported a 24% increase in total revenue for Q3 2022, reaching $37 million, driven by a 121% surge in drug discovery revenue. The company's software revenue remained stable at $24.7 million. However, operating expenses rose 38% to $63.4 million, resulting in a net loss of $39.9 million. Schrödinger has narrowed its full-year revenue guidance to $167 million to $175 million. Exciting developments include the opening of a Phase 1 trial for MALT1 inhibitor SGR-1505 and upcoming data presentations for CDC7 inhibitor SGR-2921 at the ASH meeting.

Schrödinger, Inc. (Nasdaq: SDGR) has announced the presentation of new preclinical data on its CDC7 inhibitor, SGR-2921, at the American Society of Hematology's 64th Annual Meeting in New Orleans from December 10-13, 2022. CDC7 is a cell cycle kinase crucial for DNA replication, and its inhibition serves as a promising approach for treating cancers like acute myeloid leukemia (AML). The company plans to initiate a Phase 1 trial of SGR-2921 for relapsed/refractory AML in the second half of 2023.

Schrödinger (Nasdaq: SDGR) will release its third quarter 2022 financial results on November 3, 2022, after market close, followed by a conference call at 4:30 p.m. ET. Participants can access the live webcast through the company’s investor website. Schrödinger is focused on transforming therapeutics and materials discovery via its physics-based computational platform, which speeds up molecule discovery for drug development and materials applications while reducing costs. Established in 1990, the company operates globally with over 700 employees.

Schrödinger (Nasdaq: SDGR) showcased its physics-based computational platform at its Platform Day on October 6, highlighting its role in drug discovery across 30 collaborations. Notably, a new collaboration with Lilly will yield an upfront payment and potential milestone payments totaling up to $425 million. The company is advancing 12 collaborations and 18 proprietary programs. CEO Ramy Farid emphasized the platform's innovative potential, while CFO Geoffrey Porges noted positive business metrics and increasing royalty opportunities.